By Bernadette Toner

Quidel's molecular diagnostic development programs are running ahead of schedule, with the first assays from the initiative expected to be available outside the US in the fall, company officials said recently.

In a conference call to discuss Quidel's first-quarter financial results, Doug Bryant, president and CEO, shed additional light on the company's molecular diagnostic initiative.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.